

B1  
4. (Amended) A method of treatment of a disease selected from the group consisting of conjunctivitis, keratitis, ["allergic eyes,"] and anterior uveitis, which method comprises administering to the eye an effective amount of an ophthalmically acceptable aqueous pharmaceutical solution containing [an] the active ingredient 9-ethyl-6, -dihydro-4, 6-dioxo-10-propyl-4H-pyrano(3,2g)quinoline-2, 8-dicarboxylic acid, or a pharmaceutically acceptable salt thereof.

#### REMARKS


Claim 4 has been amended to remove the quotation marks around the words "allergic eyes" and the word "an" was removed and the word "the" was inserted after the word "containing" and before the word "active".

In accordance with 37 CFR 1.178, the original Letters Patent # 5,443,833 is surrendered to the U.S.P.T.O.

Additionally, pursuant to 37 CFR 3.73(b) enclosed is a copy of the executed assignment by the named inventors in favor of the assignee. As indicated, this assignment has been recorded in the U.S.P.T.O. (Reel 4864, frame 113).

In view of the foregoing, it is submitted that the reissue application is in condition for allowance, an early notice of which is earnestly solicited.

Respectfully submitted,



Edward W. Goldstein

Reg. No. 22945

TOBOR, GOLDSTEIN & HEALEY, L.L.P.

1177 West Loop South, 10<sup>th</sup> Floor

Houston, TX 77027

Telephone: 713/877-1515

Facsimile: 713/877-1737